Miflonide (Budesonide)

Budesonide, the active ingredient in Miflonide, is a glucocorticoid presented as an inhalation formulation for inhalation use. It reduces airway inflammation and is indicated for the management of asthma and chronic obstructive pulmonary disease (COPD) in adults and children where appropriate, helping to improve breathing and lower the risk of exacerbations.

GNH USA supplies Miflonide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, providing reliable access to this inhaled corticosteroid for qualified healthcare providers.

Miflonide, an inhaled glucocorticoid, is used to treat inflammatory airway diseases.

- Asthma: improves symptom control and reduces the frequency of asthma attacks. - Chronic obstructive pulmonary disease (COPD): decreases airway inflammation and helps prevent COPD exacerbations. - Maintenance therapy for chronic respiratory disease: provides long‑term anti‑inflammatory protection to sustain lung function.

Adverse reactions may occur with inhaled Budesonide therapy.

Common Side Effects: - Oral candidiasis (thrush) - Hoarseness or dysphonia - Cough or throat irritation - Headache

Serious or Rare Side Effects: - Adrenal suppression - Pneumonia, especially in COPD patients - Severe fungal infections - Decreased bone mineral density - Cataracts or glaucoma

Use Miflonide with attention to specific safety considerations.

- Infection risk: assess for active respiratory infections before initiating therapy. - Growth monitoring: regularly evaluate growth in pediatric patients. - Administration technique: use a spacer device to minimize oral deposition. - Discontinuation: taper gradually to avoid adrenal insufficiency. - Concomitant immunosuppressants: monitor for additive immunosuppressive effects. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Budesonide may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Ritonavir: can markedly raise Budesonide levels. - Systemic glucocorticoids: risk of additive adrenal suppression.

Moderate Interactions (Monitor Closely): - Fluconazole: may modestly increase Budesonide concentrations. - Macrolide antibiotics (e.g., clarithromycin): potential for increased exposure. - Diuretics: monitor electrolytes as hypokalemia risk may rise.